Smith & Nephew plc · LSE:SN.
Smith & Nephew — Q1 2015 Earnings Presentation
15 slides from Smith & Nephew's earnings presentation, 2015
Slide 1: 2015 First Quarter Trading Report
2015 First Quarter Trading Report
Slide 2: Forward looking statements
Forward looking statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "in
Slide 3: Olivier Bohuon, Chief Executive Officer
Olivier Bohuon Chief Executive Officer
Slide 4: Q1 revenue growth of 3% underlying
Q1 revenue growth of 3% underlying Geographical growth Revenue split Product franchise growth Sports Medicine Joint Repair 9% Arthroscopic Enabling Tech -2% 1% US Trauma & 5% Extremities Other Surgical 11% Knees 2% -2% Est OUS Hips -1% 9% AWC 5% Emerging 22% AWB -27% AWD -4% 0% 4% 8% 12% 16% 20% -20
Slide 5: Sports Medicine, Trauma & OSB
Sports Medicine, Trauma & OSB • Revenue performance ‐ Sports Medicine Joint Repair +9% ($144m) ‐ Arthroscopic Enabling Technologies (AET) -2% ($140m) ‐ Trauma & Extremities +5% ($123m) ‐ Other Surgical Businesses* +11% ($47m) • Commentary Q-FIX◊ ‐ ArthroCare integration completed All Suture Anchor ‐
Slide 6: Reconstruction
Reconstruction • Revenue performance ‐ Knees: global +2%, US +3%, OUS +2% ($209m) ‐ Hips: global -1%, US -1%, OUS -1% ($151m) OXINIUM◊ • Commentary More than one million joints ‐ JOURNEY◊ II continued strong growth ‐ new VERILAST◊ Technology for Hips and Knees campaign in the US started well 6
Slide 7: Advanced Wound Management
Advanced Wound Management • Revenue performance ‐ Advanced Wound Care +9% ($178m) ‐ Advanced Wound Bioactives +5% ($75m) ‐ Advanced Wound Devices -27% ($37m) • Commentary ‐ improving trend in AWC ALLEVYN◊ Life ‐ AWB exhibited increased seasonality Standard Heel ‐ strong PICO◊ growth; offset by US tr
Slide 8: Q1 summary and guidance
Q1 summary and guidance • Good start to the year • Full year guidance unchanged ‐ H1 / H2 margin phasing ‐ updated FX expectations • Expect improvement as year progresses 8
Slide 9: Questions
Questions a 5 e 7.4 smith&nephew Supporting healthcare professionals for over 150 years
Slide 10: Appendices
> smith&nephew Appendices
Slide 11: Revenue growth reconciliation
Revenue growth reconciliation Underlying Acquisitions Currency Reported % % % % Quarter 1* 3 8 (8) 3 FX Guidance**: Full year impact of -7% Q2 impact of -9% * Q1 2015 comprises 61 trading days (2014 – 62 trading days) ** Based on FX rates on 28 April 2015 11
Slide 12: Franchise revenue analysis
Franchise revenue analysis 2014 2015 Q1 Q2 Q3 Q4 Full Year Q1 Growth Growth Growth Growth Growth Revenue Growth % % % % % $m % Sports Medicine, Trauma & OSB 2 6 7 5 5 454 5 Sports Medicine Joint Repair 5 9 11 8 8 144 9 Arthroscopic Enabling Technologies (2) (1) 3 2 1 140 (2) Trauma & Extremities (1)
Slide 13: Regional revenue analysis
Regional revenue analysis 2014 2015 Q1 Q2 Q3 Q4 Full Year Q1 Growth Growth Growth Growth Growth Revenue Growth % % % % % $m % Geographic regions US (2) 4 2 - 1 510 1 Other Established Markets 1 (3) (2) (1) (1) 422 (2) Established Markets (1) 1 - - - 932 - Emerging Markets 9 17 20 18 17 172 22 Group
Slide 14: Business days per quarter
Business days per quarter Q1 Q2 Q3 Q4 Full Year 2014 62 63 63 63 251 2015 61 63 63 64 251 14
Slide 15: o/. A smith&nephew
o/. A 74 smith&nephew Supporting healthcare professionals for over 150 years